F
JAZZ icon

FutureAdvisor’s Jazz Pharmaceuticals JAZZ Stock Holding History

FutureAdvisor’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-6,663
Closed -$336K – 61
2014
Q4 		$336K Buy
+6,663
New +$1.11M 0.11% 43

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FutureAdvisor's JAZZ Position: Q1 2015 in Review

FutureAdvisor sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2015, closing a stake of 6,663 shares — an estimated $336K sold.

FutureAdvisor first reported a position in JAZZ in Q4 2014 and held it in 1 quarter. The position peaked at $336K in Q4 2014. 354 funds tracked by Wall St. Rank hold JAZZ as of Q1 2015.

  • FutureAdvisor reported no remaining Jazz Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • FutureAdvisor sold 6,663 Jazz Pharmaceuticals shares in Q1 2015, an estimated $336K.
  • FutureAdvisor first reported a position in Jazz Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • FutureAdvisor's Jazz Pharmaceuticals position peaked at $336K in Q4 2014.
  • 354 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2015.

Based on FutureAdvisor's 13F filing for Q1 2015, filed 15 May 2015.